Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01323751 · ClinicalTrials.gov registry record · Phase 1
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT01323751 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 120 participants.
The verdict
NCT01323751, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
Phase 1(a \& b): To evaluate the side effects and determine the best dose of oral ACY-1215 as monotherapy, and also in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. Phase 2a: To determine the objective response rate of oral ACY-1215 in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
Interventions
- DRUG ACY-1215
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2011-07 |
| Est. Completion | 2016-12-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01323751
The ClinicalTrials.gov registry entry for NCT01323751 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ACY-1215 is the first listed.
NCT01323751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01323751 about?
NCT01323751 is a clinical study titled "Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma". Phase 1(a \& b): To evaluate the side effects and determine the best dose of oral ACY-1215 as monotherapy, and also in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. Phase 2a: To determine the objective response rate of oral ACY-1215...
What is the current status of trial NCT01323751?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2011-07. Estimated completion is 2016-12-03.
What interventions are being tested in trial NCT01323751?
The interventions under investigation include: ACY-1215 (DRUG).
Who is sponsoring clinical trial NCT01323751?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.